Stem Cells http://www.stemcellsportal.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Vries, E. G.
Right arrow Articles by Willemse, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Vries, E. G.
Right arrow Articles by Willemse, P. H.

Stem Cells, Vol 11, 72-80, Copyright © 1993 by AlphaMed Press

REVIEWS

Recombinant human interleukin 3 in clinical oncology

EG de Vries, MM van Gameren and PH Willemse
Department of Internal Medicine, University Hospital, Groningen, The Netherlands.

Interleukin 3 (IL-3) is a multipotent hematopoietic growth factor which became available as a recombinant (rh) growth factor for use in the clinic a few years ago. In dose-finding studies, this hematopoietic growth factor has been evaluated without and after standard chemotherapy. Stimulatory effects on leukocytes, neutrophils, eosinophils, monocytes, reticulocytes and platelets were observed in some studies. Chemotherapy postponement due to insufficient bone marrow recovery was less frequent when IL-3 was administered. There are some clinical studies available in which rhIL-3 is combined with rh granulocyte-macrophage colony-stimulating factor (GM-CSF). The results do not clearly suggest superiority of these combinations over rhGM-CSF alone, but this may be partly due to the time scheduling of the growth factors. Administration s.c. is not inferior to i.v. Side effects mainly consist of flu-like symptoms and headache. The role of rhIL-3 after high-dose chemotherapy and autologous bone marrow reinfusion is still questionable. The addition of rhIL-3 to rhGM-CSF both administered after chemotherapy may allow a very high yield of peripheral stem cells suitable for bone marrow reconstitution after high-dose chemotherapy. rhIL-3 can stimulate leukemia tumor cell proliferation in vitro as well as proliferation of solid tumor cell lines. It is not yet clear in which way rhIL-3 combined with chemotherapy will effect tumor response and patient survival. It is too early to define the exact place of rhIL-3 in oncology. Additional studies with rhIL-3 alone and in combination with other growth factors are needed.


This article has been cited by other articles:


Home page
 JCOHome page
S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella
Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy
J. Clin. Oncol., March 13, 2000; 18(6): 1360 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
M. Eder, G. Geissler, and A. Ganser
IL-3 in the Clinic
Stem Cells, September 1, 1997; 15(5): 327 - 333.
[Abstract] [Full Text]

Home page
 ANGIOLOGYHome page
G. Sigounas, M. Steiner, A. Anagnostou, and G. Sigounas
Synergism of Hemopoietic Growth Factors on Endothelial Cell Proliferation
Angiology, February 1, 1997; 48(2): 141 - 147.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.stemcellsportal.com/
Copyright © 1993 by AlphaMed Press.